Author

M. Ninkov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Y. Kang· 2 shared N. Saeedian· 2 shared R. M. Troyer· 2 shared R. Rashu· 2 shared S. M. M. Haeryfar· 2 shared A. A. Ashkar· 1 shared A. Zhang· 1 shared C. G. Richer· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. Y. Kang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting the MR1-MAIT Cell Axis Improves Vaccine Efficacy and Affords Protection against Viral Pathogens

R. Rashu, M. Ninkov, C. M. Wardell, J. M. Benoit, N. I. Wang, M. R. D'Agostino, A. Zhang, E. Feng, N. Saeedian, G. I. Bell, F. Vahedi, D. A. Hess, R. M. Troyer, C. Y. Kang, A. A. Ashkar, , S. M. M. Haeryfar

This study shows that targeting the MR1-MAIT cell axis with 5-OP-RU enhances vaccine efficacy against viral pathogens by expanding and reprogramming MAIT cells.

PLOS Pathogens · Jun 29, 2023Peer-reviewedImmunology

Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants

K. A. Parham, G. N. Kim, N. Saeedian, M. Ninkov, C. G. Richer, Y. Li, K. Wu, R. Rashu, S. D. Barr, E. J. Arts, S. M. M. Haeryfar, C. Y. Kang, R. M. Troyer

This study evaluates rVSV-based vaccines against SARS-CoV-2 variants, showing potent neutralizing antibodies and CD8+ T cell responses across multiple variants.

bioRxiv · Jul 19, 2022 · PreprintImmunology